<DOC>
	<DOC>NCT01307397</DOC>
	<brief_summary>This open-label, multicenter study will evaluate the safety and efficacy of RO5185426 in patients with BRAF V600 mutation-positive, surgically incurable and unresectable stage IIIC or IV metastatic melanoma. Eligible patients will receive RO5185426 (960 mg twice daily orally) until disease progression or unacceptable toxicity occurs, with a safety follow-up of 24 months after discontinuation of the study drug.</brief_summary>
	<brief_title>A Study of RO5185426 in Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Adult patients, &gt;/= 16 years of age Histologically confirmed metastatic melanoma (surgically incurable and unresectable stage IIIC or stage IV; AJCC) with BRAF V600 mutation determined by Cobas 4800 BRAF Mutation Test Patients may or may not have received prior systemic therapy for metastatic melanoma Eastern Cooperative Oncology Group (ECOG) performance status 02 Adequate hematologic, renal and liver function Evidence of symptomatic CNS lesions, use of steroids or antiseizure medications for treatment of brain metastases prior to the first administration of RO5185426 Previous malignancy (other than melanoma) within the past 2 years, except for treated and controlled basal or squamous cell carcinoma of the skin or carcinoma insitu of the cervix Concurrent administration of any anticancer therapies other than those administered in the study Clinically significant cardiovascular disease or event within the 6 months prior to first administration of study drug Refractory nausea or vomiting, external biliary shunt, or significant bowel resection that would preclude adequate absorption</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>